Abbvie INC Form 4 insider transactions

EVP and CFO of AbbVie, Scott T. Reents, reports disposition of shares to cover tax obligations.

Perry C. Siatis, EVP, GC AND SECRETARY of AbbVie Inc., reports multiple transactions involving AbbVie common stock, including sales and acquisitions through option exercises.

EVP and Chief Operations Officer of AbbVie, Azita Saleki-Gerhardt, reports the sale of 17,056 shares of common stock on February 28, 2025.

AbbVie's CEO, Robert A. Michael, reports the disposition of 27,186 shares of common stock to cover tax obligations.

EVP and Chief Commercial Officer of AbbVie, Jeffrey Ryan Stewart, sold shares of common stock to satisfy tax withholding obligations related to the vesting of restricted stock units.

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the sale of AbbVie common stock in multiple transactions.

AbbVie's SVP, Controller Kevin K. Buckbee, reports the acquisition and disposal of AbbVie common stock and stock options on February 26, 2025.

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the sale of common stock and exercise of stock options on February 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Perry C. Siatis, EVP, GC, and Secretary of AbbVie Inc., sold a total of 5,778 shares of common stock on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Kevin K. Buckbee, SVP and Controller at AbbVie, reports the vesting of performance-based stock awards and the grant of stock options.

Roopal Thakkar, EVP, R&D and CSO of AbbVie, reports the acquisition of shares and options related to performance-based awards and an incentive stock program.

EVP, Chief Commercial Officer of AbbVie, Jeffrey Ryan Stewart, reports the vesting of stock awards and options, significantly increasing his holdings in the company.

EVP, GC AND SECRETARY Perry C. Siatis reports acquisition of AbbVie shares through performance share awards and stock options, along with the release of performance-vesting restrictions.

Azita Saleki-Gerhardt, EVP and Chief Operations Officer of AbbVie, acquired shares and options through performance-based awards and an employee stock option, increasing her beneficial ownership in the company.

EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the vesting of performance-based stock awards and the grant of stock options.

EVP, Chief Business and Strategy Officer of AbbVie, Nicholas Donoghoe, reports acquisition of shares and options related to performance-based awards.

EVP and CFO of AbbVie, Scott T. Reents, reports the vesting of performance-based stock awards and a new stock option grant.

AbbVie CEO Robert A. Michael reports the acquisition of shares and options related to performance-based awards, along with the release of performance-vesting restrictions on previously granted stock units.

Director Richard Gonzalez reports the vesting of performance-based shares and stock options in AbbVie, increasing his beneficial ownership.

Roopal Thakkar, EVP, R&D and CSO of AbbVie, files an amendment to a previous SEC Form 4 to correct errors in reported stock awards and option exercise price.

Director Susan E. Quaggin reports acquisition of AbbVie stock equivalent units through director fees and dividend reinvestment.

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

Director Edward J. Rapp reports acquiring stock equivalent units in AbbVie Inc. due to director fees and dividend reinvestment.

AbbVie's SVP, Controller Kevin K. Buckbee, reports the exercise of stock options and the sale of shares on December 16, 2024.

Director Edward J. Rapp reports acquisition of stock equivalent units and adjustments to holdings in AbbVie Inc.

Richard Gonzalez, Executive Chairman of AbbVie, reported gifting a portion of his AbbVie common stock holdings on September 30, 2024.

Director Robert J. Alpern reports acquisition of AbbVie stock equivalent units through director fees and dividend reinvestment.

Director Susan E. Quaggin reports acquisition of AbbVie stock equivalent units as part of director fees.

EVP, Chief Operations Officer of AbbVie, Azita Saleki-Gerhardt, reports the disposition of 25,630 shares of common stock on September 24, 2024.

Richard Gonzalez, Executive Chairman of AbbVie, sold 66,500 shares of common stock at a weighted average price of $186.52 on August 5, 2024.